Latest Market Access News

Carnaby Resources has delivered a robust Pre-Feasibility Study and declared its maiden Ore Reserve at the Greater Duchess Copper Gold Project, setting sights on first production in the second half of 2026.

Sovereign Metals' March 2026 update reveals a robust DFS for its Kasiya Rutile-Graphite Project, a substantial resource upgrade, strategic offtake MOUs, and a high-value heavy rare earth by-product discovery.

Lake Resources made solid progress on the Exploitation Environmental Impact Assessment for its Kachi Lithium Brine Project, targeting approval in Q3 2026, while maintaining strong liquidity and strategic partnerships.

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

Elsight’s Halo connectivity platform has gained critical approval on the U.S. Department of War’s DCMA Blue List, enabling rapid military procurement amid a historic US$75 billion drone budget surge.

Nexsen Limited has cleared a major FDA regulatory hurdle for its StrepSure rapid Group B Streptococcus test, confirmed a clear 510(k) submission pathway, and secured over A$1.7 million in non-dilutive grants to expand clinical validation and market rollout in Asia-Pacific and neonatal diagnostics.

OncoSil Medical reported a 60% year-on-year increase in dose sales in Q3 FY26, boosted by expanding treatment centres and advancing clinical trials, while cost-cutting and a new manufacturing facility aim to underpin growth.

Proteomics International is pivoting from research to disciplined commercial execution of its proteomics-based diagnostic tests, focusing on distributor partnerships and reimbursement pathways in Australia and the US.

Streamplay Studio delivers a fourth consecutive quarter of positive cash flow, underpinned by steady publishing revenues and strategic platform growth in new regions.

Algorae Pharmaceuticals has struck an exclusive commercial and licensing agreement with global pharma Zydus Lifesciences to bring 10 injectable, oral, and specialty medicines to Australia and New Zealand, pending regulatory approvals.

Imricor Medical Systems advanced FDA clearances and expanded clinical trials in Q1 CY26, positioning for commercial growth despite higher operating cash outflows.

Vitrafy Life Sciences completed Phase II of its U.S. Military platelet cryopreservation study with strong results for a simplified no-wash process, accelerating commercial interest and progressing FDA device registration despite manufacturing delays.